A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1698 participants.

Also called NCT06045221

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,698 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06045221
Other papers using this trial's data
  • Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Lancet (London, England), 2026-03-21 DOI, PubMed 41765029

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, China, Japan, Mexico, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06045221. Randomized; no masking; primary purpose treatment. Start 2023-09-22 (actual); primary completion 2025-08-22 (actual). Results posted on 2026-09-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Acronym
ACHIEVE-3
Intervention (Drug)
Orforglipron
Intervention (Drug)
Semaglutide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06045221
Content hash
1c28f4582c463a5e2af342efb08a0d1fc515d0a876506a8900c7a9ed940afb81